- Home
- AMLX vs VERA Comparison
AMLX vs VERA Comparison
Compare AMLX & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMLX
- VERA
- Stock Information
- Founded
- AMLX 2014
- VERA 2016
- Country
- AMLX United States
- VERA United States
- Employees
- AMLX N/A
- VERA N/A
- Industry
- AMLX Biotechnology: Pharmaceutical Preparations
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- AMLX Health Care
- VERA Health Care
- Exchange
- AMLX Nasdaq
- VERA Nasdaq
- Market Cap
- AMLX 1.3B
- VERA 1.5B
- IPO Year
- AMLX 2022
- VERA 2021
- Fundamental
- Price
- AMLX $14.79
- VERA $28.61
- Analyst Decision
- AMLX Strong Buy
- VERA Buy
- Analyst Count
- AMLX 7
- VERA 9
- Target Price
- AMLX $17.43
- VERA $62.75
- AVG Volume (30 Days)
- AMLX 1.5M
- VERA 1.6M
- Earning Date
- AMLX 11-06-2025
- VERA 11-05-2025
- Dividend Yield
- AMLX N/A
- VERA N/A
- EPS Growth
- AMLX N/A
- VERA N/A
- EPS
- AMLX N/A
- VERA N/A
- Revenue
- AMLX N/A
- VERA N/A
- Revenue This Year
- AMLX N/A
- VERA N/A
- Revenue Next Year
- AMLX N/A
- VERA N/A
- P/E Ratio
- AMLX N/A
- VERA N/A
- Revenue Growth
- AMLX N/A
- VERA N/A
- 52 Week Low
- AMLX $2.60
- VERA $18.53
- 52 Week High
- AMLX $16.96
- VERA $51.27
- Technical
- Relative Strength Index (RSI)
- AMLX 60.27
- VERA 50.88
- Support Level
- AMLX $11.93
- VERA $27.55
- Resistance Level
- AMLX $15.09
- VERA $29.90
- Average True Range (ATR)
- AMLX 1.00
- VERA 2.02
- MACD
- AMLX 0.14
- VERA 0.06
- Stochastic Oscillator
- AMLX 89.70
- VERA 62.09
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.